Corcept在SGO重磅会议公布Rosella关键试验完整数据：《柳叶刀》同步发表Lifyorli™联合白蛋白紫杉醇显著延长铂耐药卵巢癌患者总生存期

美股速递04-11

Corcept医疗（Corcept Therapeutics）于美国妇科肿瘤学会（SGO）年会重磅环节公布了其关键性Rosella试验的完整数据，同时国际顶级医学期刊《柳叶刀》同步发表了相关研究成果。研究证实，其创新药物Lifyorli™（relacorilant）联合白蛋白紫杉醇治疗方案，能够显著改善铂类药物耐药性卵巢癌患者的总生存期。

这一突破性进展为缺乏有效治疗手段的铂耐药卵巢癌患者提供了新的希望，也彰显了靶向皮质醇调节疗法在肿瘤治疗领域的应用潜力。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1184877931?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-11 04:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184877931","market":"us","top_or_hot":-1,"title":"Corcept在SGO重磅会议公布Rosella关键试验完整数据：《柳叶刀》同步发表Lifyorli™联合白蛋白紫杉醇显著延长铂耐药卵巢癌患者总生存期","media":"美股速递","content":"<p>Corcept医疗（Corcept Therapeutics）于美国妇科肿瘤学会（SGO）年会重磅环节公布了其关键性Rosella试验的完整数据，同时国际顶级医学期刊《柳叶刀》同步发表了相关研究成果。研究证实，其创新药物Lifyorli™（relacorilant）联合白蛋白紫杉醇治疗方案，能够显著改善铂类药物耐药性卵巢癌患者的总生存期。</p>\n<p>这一突破性进展为缺乏有效治疗手段的铂耐药卵巢癌患者提供了新的希望，也彰显了靶向皮质醇调节疗法在肿瘤治疗领域的应用潜力。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept在SGO重磅会议公布Rosella关键试验完整数据：《柳叶刀》同步发表Lifyorli™联合白蛋白紫杉醇显著延长铂耐药卵巢癌患者总生存期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept在SGO重磅会议公布Rosella关键试验完整数据：《柳叶刀》同步发表Lifyorli™联合白蛋白紫杉醇显著延长铂耐药卵巢癌患者总生存期\n</h2>\n\n<h4 class=\"meta\">\n\n2026-04-11 04:46 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corcept医疗（Corcept Therapeutics）于美国妇科肿瘤学会（SGO）年会重磅环节公布了其关键性Rosella试验的完整数据，同时国际顶级医学期刊《柳叶刀》同步发表了相关研究成果。研究证实，其创新药物Lifyorli™（relacorilant）联合白蛋白紫杉醇治疗方案，能够显著改善铂类药物耐药性卵巢癌患者的总生存期。\n这一突破性进展为缺乏有效治疗手段的铂耐药卵巢癌患者提供了新...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"","article_id":"1184877931","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184877931","pubTimestamp":1775853973,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Corcept医疗（Corcept Therapeutics）于美国妇科肿瘤学会（SGO）年会重磅环节公布了其关键性Rosella试验的完整数据，同时国际顶级医学期刊《柳叶刀》同步发表了相关研究成果。研究证实，其创新药物Lifyorli™（relacorilant）联合白蛋白紫杉醇治疗方案，能够显著改善铂类药物耐药性卵巢癌患者的总生存期。\n这一突破性进展为缺乏有效治疗手段的铂耐药卵巢癌患者提供了新的希望，也彰显了靶向皮质醇调节疗法在肿瘤治疗领域的应用潜力。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4532":"文艺复兴科技持仓","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药","CORT":"Corcept医疗","LU0566484027.USD":"安本美国小盘成长股"},"translate_title":"Corcept Announces Full Data of Rosella Key Trial at SGO Blockbuster Conference: The Lancet Simultaneously Publishes Lifyorli ™ Combination with albumin paclitaxel significantly prolongs overall survival in patients with platinum-resistant ovarian cancer","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Corcept医疗（Corcept Therapeutics）于美国妇科肿瘤学会（SGO）年会重磅环节公布了其关键性Rosella试验的完整数据，同时国际顶级医学期刊《柳叶刀》同步发表了相关研究成果。研究证实，其创新药物Lifyorli™（relacorilant）联合白蛋白紫杉醇治疗方案，能够显著改善铂类药物耐药性卵巢癌患者的总生存期。\n这一突破性进展为缺乏有效治疗手段的铂耐药卵巢癌患者提供了新的希望，也彰显了靶向皮质醇调节疗法在肿瘤治疗领域的应用潜力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184877931","isCrawlerRequest":true}